KV PHARMACEUTICAL CO

Inactive Instrument

Press Releases KV Pharmaceutical Co

Equities

US4827402060

End-of-day quote Nyse Other stock markets
- ^USD	-

2012

K-V Pharmaceutical Company : K-V Pharmaceutical files for bankruptcy protection

RE

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

KV Pharmaceutical Co : Ther-Rx Corporation and Perrigo Company Announce the Availability of Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%) for Prescribing	25/01/13	PU
KV Pharmaceutical Co : K-V Pharmaceutical Receives Court Approval of Hologic Settlement	01/01/13	PU
KV Pharmaceutical Co : K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization	19/12/12	PU
K-V Pharmaceutical Company : K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court	10/08/12	PU
K-V Pharmaceutical Company : K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court	08/08/12	PR
K-V Pharmaceutical Company : K-V Pharmaceutical Announces Planned Transition of Trading of Class A and Class B Common Shares to the OTC Markets	06/08/12	PU
K-V Pharmaceutical Company : Files Voluntary Petitions for Reorganization to Restructure Financial Obligations	04/08/12	PU
K-V Pharmaceutical Company : Announces Additional Notification from NYSE Regarding Listing Criteria	20/07/12	PR
K-V Pharmaceutical Company : Announces Notification from NYSE Regarding Listing Criteria	29/06/12	PR
K-V Pharmaceutical Company : to Present at Imperial Capital 2012 Healthcare Investor Forum	12/04/12	PR
K-V Pharmaceutical Company : to Present at Needham & Company 11th Annual Healthcare Conference	02/04/12	PR
K-V Pharmaceutical Company : K-V Pharmaceutical Announces Updated Makena® Performance Metrics and Investor Conference Call	09/02/12	PR
K-V Pharmaceutical Company : Comments on Recent Settlement with the Department of Justice	07/12/11	PU
K-V Pharmaceutical Company : Independent Laboratory Testing Demonstrates Important Quality Differences Between FDA-Approved Makena® and Compounded 17P Formulations	09/11/11	PU
K-V Pharmaceutical Company : K-V Pharmaceutical Announces Updated Makena® Performance Metrics	08/11/11	PR
KV PHARMA'A' : K-V PHARMACEUTICAL COMMENTS ON ACOG AND SMFM INFORMATION UPDATE REGARDING 17-ALPHA HYDROXYPROGESTERONE CAPROATE – FDA-APPROVED MAKENA™ AND COMPOUNDED 17P	13/10/11	PU
KV PHARMA'A' : K-V Pharmaceutical Company to Present at Imperial Capital's 5th Annual Global Opportunities Conference	28/09/11	PR
KV PHARMA'A' : K-V PHARMACEUTICAL COMPANY ANNOUNCES THE COMPLETION OF THE SALE OF NESHER PHARMACEUTICALS, INC. ITS GENERIC PHARMACEUTICAL BUSINESS	09/08/11	PU
KV PHARMA'A' : K-V Pharmaceutical Company Announces Filing of First Quarter Fiscal 2012 Form 10-Q and Schedules Investor Conference Call	09/08/11	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Secure my Investments

fermer